Polpharma continues to invest, grow and catch up its competitors

Drug producer Polpharma will increase its capital by zł. 50 million in November. The move is related to privatization obligations dating from a deal signed three years ago. Over this period the company's turnover increased by over 46%, from zł. 552 million in 1999 to almost zł. 810 million by the end of last year. By 2007 Polpharma will have invested over zł. 600 million on research and development related to employing new technology to produce medicines. The concern plans to introduce 71 new medicine on the market. "This issue is not only up to us, but also dependent on how fast the office for drug registration works," said Polpharma's president Pavel Mirovsky. He added that the company plans to become a sector leader with a 12% market share. Presently it is just 1.5% behind its main competitor, Glaxo. (Puls Biznesu, p. 8) A.K.